An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
C16038 (MM-6)

To Learn More Call
(201)-510-0950